- Recommendation ID
Prescribing beyond monotherapy:- What is the clinical and cost effectiveness of various ADHD prescribing strategies when monotherapy has failed?
- Any explanatory notes
Why is this important:- This guideline makes recommendations for the medication choices for people with ADHD up to the point at which common monotherapies are exhausted. There is very little evidence to guide healthcare professionals beyond this point, particularly with regard to whether there is a benefit of prescribing stimulant and non-stimulant medication together.
Source guidance details
- Comes from guidance
- Attention deficit hyperactivity disorder: diagnosis and management
- Date issued
- March 2018
|Is this a recommendation for the use of a technology only in the context of research?||No|
|Is it a recommendation that suggests collection of data or the establishment of a register?||No|